# Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC

> **NCT06371586** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 67 (estimated)

## Conditions studied

- Gastric Cancer
- Diffuse Type Carcinoma

## Interventions

- **DRUG:** Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy

## Key facts

- **NCT ID:** NCT06371586
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06371586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06371586, "Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06371586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*